271 related articles for article (PubMed ID: 27878207)
21. More than a decade of international experience with a pdFVIII/VWF concentrate in immune tolerance.
Santagostino E
Haemophilia; 2013 Jan; 19 Suppl 1():8-11. PubMed ID: 23278994
[TBL] [Abstract][Full Text] [Related]
22. Challenges of the management of severe hemophilia A with inhibitors: two case reports emphasizing the potential interest of a high-purity human Factor VIII/von Willebrand factor concentrate and individually tailored prophylaxis guided by thrombin-generation test.
Mathieu S; Crampe C; Dargaud Y; Lavigne-Lissalde G; Escuriola-Ettingshausen C; Tardy B; Meley R; Thouvenin S; Stephan JL; Berger C
Blood Coagul Fibrinolysis; 2015 Dec; 26(8):940-5. PubMed ID: 26517064
[TBL] [Abstract][Full Text] [Related]
23. The role of natural VWF/FVIII complex concentrates in contemporary haemophilia care: a guideline for the next decade.
Mannucci PM
Haemophilia; 2012 May; 18 Suppl 2():2-7. PubMed ID: 22530573
[TBL] [Abstract][Full Text] [Related]
24. VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study.
Gringeri A
Haemophilia; 2007 Dec; 13 Suppl 5():73-7. PubMed ID: 18078402
[TBL] [Abstract][Full Text] [Related]
25. ITI choice for the optimal management of inhibitor patients - from a clinical and pharmacoeconomic perspective.
Oldenburg J; Austin SK; Kessler CM
Haemophilia; 2014 Sep; 20 Suppl 6():17-26. PubMed ID: 24975701
[TBL] [Abstract][Full Text] [Related]
26. Neutralizing capacity of inhibitors on FVIII is lower for natural FVIII/VWF complex than for isolated FVIII: in vitro comparative study in eleven different therapeutic FVIII concentrates.
Bravo MI; Ortiz AM; Costa M; Grancha S; Jorquera JI
Haemophilia; 2016 Jul; 22(4):e341-4. PubMed ID: 27354216
[No Abstract] [Full Text] [Related]
27. Adult haemophilia A patients with inhibitors: successful immune tolerance induction with a single FVIII/VWF product.
Rangarajan S; Jiménez-Yuste V; Santagostino E
Haemophilia; 2014 Nov; 20(6):e414-7. PubMed ID: 25333452
[No Abstract] [Full Text] [Related]
28. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project.
Fischer K; Lassila R; Peyvandi F; Calizzani G; Gatt A; Lambert T; Windyga J; Iorio A; Gilman E; Makris M;
Thromb Haemost; 2015 May; 113(5):968-75. PubMed ID: 25567324
[TBL] [Abstract][Full Text] [Related]
29. Successful immune tolerance induction with factor VIII/von Willebrand factor concentrate in an elderly patient with severe haemophilia A and a high responder inhibitor.
Rivolta GF; Di Perna C; Franchini M; Riccardi F; Ippolito L; Lombardi M; Tagliaferri A
Blood Transfus; 2010 Jan; 8(1):66-8. PubMed ID: 20104281
[No Abstract] [Full Text] [Related]
30. Epidemiology of inhibitors and current treatment strategies.
Kreuz W; Ettingshausen CE; Auerswald G; Saguer IM; Becker S; Funk M; Heller C; Klarmann D; Klingebiel T;
Haematologica; 2003 Jun; 88(6):EREP04. PubMed ID: 12826530
[TBL] [Abstract][Full Text] [Related]
31. Frequent but low titre factor VIII inhibitors in haemophilia A patients treated with high purity concentrates.
Zanon E; Zerbinati P; Girolami B; Bertomoro A; Girolami A
Blood Coagul Fibrinolysis; 1999 Apr; 10(3):117-20. PubMed ID: 10357004
[TBL] [Abstract][Full Text] [Related]
32. The role of VWF for the success of immune tolerance induction.
Kreuz W
Thromb Res; 2008; 122 Suppl 2():S7-S12. PubMed ID: 18549910
[TBL] [Abstract][Full Text] [Related]
33. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.
Greninger DA; Saint-Remy JM; Jacquemin M; Benhida A; DiMichele DM
Haemophilia; 2008 Mar; 14(2):295-302. PubMed ID: 18081826
[TBL] [Abstract][Full Text] [Related]
34. Inhibitors: our greatest challenge. Can we minimize the incidence?
Kruse-Jarres R
Haemophilia; 2013 Jan; 19 Suppl 1():2-7. PubMed ID: 23278993
[TBL] [Abstract][Full Text] [Related]
35. Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies.
Volkers P; Hanschmann KM; Calvez T; Chambost H; Collins PW; Demiguel V; Hart DP; Hay CRM; Goudemand J; Ljung R; Palmer BP; Santagostino E; van Hardeveld EM; van den Berg M; Keller-Stanislawski B
Haemophilia; 2019 May; 25(3):398-407. PubMed ID: 31066174
[TBL] [Abstract][Full Text] [Related]
36. The role of VWF in the immunogenicity of FVIII.
Lacroix-Desmazes S; Repessé Y; Kaveri SV; Dasgupta S
Thromb Res; 2008; 122 Suppl 2():S3-6. PubMed ID: 18549909
[TBL] [Abstract][Full Text] [Related]
37. Immune Responses to Plasma-Derived Versus Recombinant FVIII Products.
Peyvandi F; Miri S; Garagiola I
Front Immunol; 2020; 11():591878. PubMed ID: 33552050
[TBL] [Abstract][Full Text] [Related]
38. Immune tolerance induction with high von Willebrand factor/factor VIII content ratio concentrate in children with haemophilia A and high-responding inhibitor.
Platokouki H; Pergantou H; Xafaki P; Komitopoulou A; Aronis S
Haemophilia; 2009 Mar; 15(2):617-9. PubMed ID: 19175417
[No Abstract] [Full Text] [Related]
39. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.
Gouw SC; van der Bom JG; Auerswald G; Ettinghausen CE; Tedgård U; van den Berg HM
Blood; 2007 Jun; 109(11):4693-7. PubMed ID: 17218379
[TBL] [Abstract][Full Text] [Related]
40. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model.
Behrmann M; Pasi J; Saint-Remy JM; Kotitschke R; Kloft M
Thromb Haemost; 2002 Aug; 88(2):221-9. PubMed ID: 12195693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
